Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Accumulated Expenses: 2020-2025

Historic Other Accumulated Expenses for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $51.3 million.

  • Xeris Biopharma Holdings' Other Accumulated Expenses rose 149.84% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.3 million, marking a year-over-year increase of 149.84%. This contributed to the annual value of $29.1 million for FY2024, which is 31.31% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Other Accumulated Expenses stood at $51.3 million, which was up 54.55% from $33.2 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Other Accumulated Expenses' 5-year high stood at $51.3 million during Q3 2025, with a 5-year trough of $6.8 million in Q3 2021.
  • In the last 3 years, Xeris Biopharma Holdings' Other Accumulated Expenses had a median value of $22.6 million in 2024 and averaged $26.2 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first surged by 184.89% in 2022, then dropped by 4.80% in 2024.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Other Accumulated Expenses stood at $15.0 million in 2021, then rose by 11.81% to $16.8 million in 2022, then spiked by 31.70% to $22.1 million in 2023, then soared by 31.31% to $29.1 million in 2024, then surged by 149.84% to $51.3 million in 2025.
  • Its last three reported values are $51.3 million in Q3 2025, $33.2 million for Q2 2025, and $30.7 million during Q1 2025.